Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Immunovia AB (publ)    IMMNOV   SE0006091997

IMMUNOVIA AB (PUBL) (IMMNOV)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
The feature you requested does not exist. However, we suggest the following feature:

Immunovia publ : Spanish Hospital Joins World’s Largest Study of Risk for Familial Pancreatic Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/12/2018 | 07:47pm CEST

 

Immunovia AB, Lund, Sweden, has announced that Clínica Universidad de Navarra will participate in PanFAM-1, the largest-ever prospective study looking at early diagnosis of familial pancreatic cancer (FPC) among high-risk individuals.

Designed to validate Immunovia’s blood-based test, IMMray PanCan-d, the study will analyze more than 1,000 individuals over 3 years, sites in the United States and Europe already offering FPC screening programs. The aim is to prove the overall healthcare benefits of testing hereditary pancreatic cancer patients.

Immunovia is also performing studies for other newly identified high-risk groups, such as patients with early onset diabetes over age 50, and patients presenting with early symptoms suggestive of pancreatic cancer. Recruitment to the global network of cancer centers is planned to end this year.

“An estimated 5% to 10% of pancreatic cancers diagnosed have a familial background, but symptoms are initially vague—such as back pain and weight loss—and could be attributed to other disorders,” says Maite Herraiz, MD, the researcher in charge of the study at Clínica Universidad de Navarra.

“Till now, we have lacked accurate noninvasive early diagnostic tools, and a blood test such as IMMray PanCan-d could make a huge difference, especially since surgical intervention at the early stages does improve survival rates significantly,” adds Mariano Ponz-Sarvisé, MD, PhD, specialist in medical oncology at the Clínica Universidad de Navarra. “We have started a screening program with individuals that qualify for inclusion in this study and we are therefore very interested to join the PanFAM-1 study along with other colleagues around the world.”

For more information, visit Immunovia and Clínica Universidad de Navarra.

 

 

Copyright © 2018 Allied Media. All rights reserved., source Health News

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOVIA AB (PUBL)
06/12IMMUNOVIA PUBL : Spanish Hospital Joins World’s Largest Study of Risk for ..
AQ
06/08IMMUNOVIA PUBL : has completed a directed share issue of approximately SEK 324 m..
AQ
06/07IMMUNOVIA PUBL : announces its intent to carry out a directed share issue
AQ
05/04IMMUNOVIA PUBL : Spanish major private hospital joins world's largest study of f..
AQ
05/03IMMUNOVIA PUBL : report from AGM
AQ
04/27IMMUNOVIA PUBL : Interim report, January-March 2018
AQ
04/25IMMUNOVIA PUBL : Invitation to presentation of Immunovia's interim report Januar..
AQ
04/12IMMUNOVIA PUBL : NYU School of Medicine joins PanFAM-1 prospective study for the..
AQ
04/04NASDAQ : Stockholm Welcomes Immunovia to the Main Market
AQ
04/03IMMUNOVIA PUBL : Kallelse till Årsstämma i Immunovia AB
AQ
More news
Financials ( SEK)
Sales 2018 27,2 M
EBIT 2018 -6,23 M
Net income 2018 -61,8 M
Finance 2018 106 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 104x
EV / Sales 2019 74,0x
Capitalization 2 944 M
Chart IMMUNOVIA AB (PUBL)
Duration : Period :
Immunovia AB (publ) Technical Analysis Chart | IMMNOV | SE0006091997 | 4-Traders
Technical analysis trends IMMUNOVIA AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
EPS Revisions
Managers
NameTitle
Mats Peter Egon Grahn Chief Executive Officer
Karl Arne Krister Borrebaeck Chairman
Lotta Blomgren Operations Director
Hans Liljenborg Chief Financial Officer
Lars Bertil Christer Wingren Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOVIA AB (PUBL)92.59%331
SARTORIUS AG48.50%10 168
MYRIAD GENETICS, INC.15.07%2 763
VAREX IMAGING CORP-6.52%1 437
DIRUI INDUSTRIAL CO LTD--.--%722
OXFORD IMMUNOTEC GLOBAL PLC3.72%375